Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
VABYSMO Inj Lös 6 mg/0.05ml Durchstf
Drug
Vabysmo, Injektionslösung
Neovaskuläre altersbedingte Makuladegeneration und diabetisches Makulaödem
11.99.0. – various
HAM – Human medicine
LSINJ – Solution for injection
BT – biological medicines
B – Dispensed on prescription by a physician or veterinarian (B)
Z – approved
5/25/2022
5/24/2027
Dosage strength
Vabysmo 6 mg/0,05 ml, Injektionslösung
Neovaskuläre altersbedingte Makuladegeneration und diabetisches Makulaödem
01
Z – approved
Package
7680683950019
No information made available
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
6 mg faricimabum
histidinum
acidum aceticum 30 per centum
methioninum
natrii chloridum
0.028 mg natrium
saccharum
polysorbatum 20
aqua ad iniectabile
acidum aceticum 30 per centum
methioninum
natrii chloridum
0.028 mg natrium
saccharum
polysorbatum 20
aqua ad iniectabile
Spezialitätenliste***
SL
-
-
971.15
None
Yes
10%
No
Authorisation holder
7601001010208
Roche Pharma (Schweiz) AG
Grenzacherstrasse 124
4058 Basel (BS)
Grenzacherstrasse 124
4058 Basel (BS)
Date of revision of the text
3/19/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.